Heart Failure Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Com

DelveInsight's, "Heart Failure - Pipeline Insight, 2025" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Heart Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Heart Failure Pipeline constitutes 70+ key companies continuously working towards developing 75+ Heart Failure treatment therapies, analyzes DelveInsight.

Heart Failure Overview:

Heart failure (HF) is a condition resulting from structural or functional heart abnormalities that impair the heart's ability to fill with or pump blood effectively, most commonly due to reduced left ventricular function. Contributing factors include ischemia, increased hemodynamic stress, neuro-hormonal overactivation, ventricular remodeling, abnormal calcium signaling, extracellular matrix changes, cell death, and genetic predisposition. Symptoms often include fatigue, breathlessness, swelling in the ankles, and exercise intolerance, though diagnosis based on symptoms alone can be difficult-especially in women, the elderly, and those with obesity. Each hospitalization for HF increases the risk of death, signaling disease progression.

HF is categorized by left ventricular ejection fraction (LVEF): reduced LVEF (



This release was published on openPR.